FDA issues alert for isoxazoline class of flea, tick productsSeptember 21, 2018The U.S. Food and Drug Administration is alerting veterinarians and pet owners of the potential for neurologic adverse events in dogs and cats when treated with isoxazoline class flea and tick products, including Bravecto, Nexgard, and Simparica. Data received by the agency as part of its routine post-marketing activities indicates that some animals receiving Bravecto, Nexgard, or Simparica have experienced adverse events such as muscle tremors, ataxia, and seizures, said the FDA in a statement. Credelio, another isoxazoline class product, recently received FDA approval. These products are approved for the treatment and prevention of flea infestations, and the treatment and control of tick infestations. The FDA said it is working with manufacturers of isoxazoline products to include new label information to highlight neurologic events, as they were seen consistently across the isoxazoline class of products. These products continue to be safe and effective for the majority of animals, said the FDA, adding that it carefully reviewed studies and other data on Bravecto, Credelio, Nexgard, and Simparica prior to approval. The agency is asking the manufacturers to change product labeling in order to provide veterinarians and pet owners with the information they need to make treatment decisions …
Education Center - SponsoredA Simpler Way to Support Clients — And Your Bottom Lineby • Paw Prosper How Paw Prosper Rewards is Changing the Way Professionals Recommend Products
Performance Dog recalls all frozen raw pet foodSeptember 19, 2018Bravo Packing Inc. of Carneys Point, N.J., has issued a voluntary recall of all Performance Dog products, a frozen raw pet food, due to potential Salmonella contamination. The company's recall comes after a sample of Performance Dog, collected during an FDA inspection, tested positive for Salmonella. No human or animal illnesses have been reported to date. Performance Dog generally works with the distributor Tefco, located in Brooklyn, which fills orders to brick-and-mortar retail stores or to consumers directly. Performance Dog comes frozen in 2-lb. and 5-lb. plastic sleeves. The recalled product has manufacture date code 071418. The manufacture date codes are printed on the boxes that contain the plastic sleeves, but not on the individual plastic sleeves. Therefore, if the cardboard box has been discarded, there are no unique identification numbers on the individual sleeves that allow customers to determine that they possess the recalled products. If you purchased this product since July 14 and cannot determine whether it is affected by the recall, the U.S. Food and Drug Administration recommends that you exercise caution and throw the product away. Consumers with questions should contact Bravo Packing Inc. at 856-299-1044, Monday - Friday 6 a.m. -2 p.m., and Saturday 4 …
Bayer, NeuroCycle partner to advance pet allergy treatmentsSeptember 18, 2018Bayer Animal Health and NeuroCycle Therapeutics Inc. have signed a global license agreement to advance allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on NeuroCycle's intellectual property. "[This] agreement underlines our strategy to combine the know-how from creative startup companies like NeuroCycle with opportunities derived from Bayer's research," said Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug discovery, external innovation and chief veterinary officer. "It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector." The companies' goal is to maximize the humanitarian impact of their innovative technologies, according to Jed Hubbs, PhD, MS, CEO of NeuroCycle Therapeutics.
Cytopoint now approved to treat canine allergic dermatitisSeptember 17, 2018Zoetis announced the U.S. Department of Agriculture (USDA) has granted an expanded indication for Cytopoint, a monoclonal antibody (mAb) therapy for the treatment of allergic dermatitis in dogs. Administered every four to eight weeks, one injection of Cytopoint works by targeting and neutralizing interleukin-31 (IL-31), a key protein involved in triggering itch in dogs, offering both convenience and sustained efficacy, according to Zoetis. "This approval gives veterinarians much-needed flexibility for personalized treatment of allergic and atopic dermatitis in dogs with two therapeutic approaches—the injectable Cytopoint and the oral tablet Apoquel," said Thomas P. Lewis II, DVM, DACVD, of Dermatology for Animals in Gilbert, Ariz. "Allergic dogs and their owners have a variety of needs, and these medications from Zoetis can bring fast and long-lasting relief to my canine allergy patients, as well as bring peace of mind to their owners." Apoquel (oclacitinib tablet) is formulated to start relieving itch within four hours and provides veterinarians with the flexibility to start and stop itch control, according to Zoetis. Cytopoint begins to relieve itch within 24 hours and provides sustained itch relief for four to eight weeks, giving the skin time to heal, the company stated. They may …
Probiotic subject of two new clinical trials in domestic dogsSeptember 14, 2018ExeGi Pharma announced two new clinical partnerships with the University of Georgia College of Veterinary Medicine and the University of Tennessee to study the company's Visbiome Vet probiotic in domestic dogs. Both studies will evaluate the probiotic's effectiveness in managing canine gastrointestinal disorders. Visbiome Vet is an eight-strain probiotic compound with a high concentration of beneficial bacteria (112.5 billion bacteria per dose); the product has been the subject of four controlled clinical trials thus far. The University of Georgia will research effects of the product on diarrhea levels in dogs postsurgery. The placebo-controlled study will evaluate the incidence and severity of diarrhea, as well as changes to the canine microbiome. The second study, conducted by the University of Tennessee Institute of Agriculture, will evaluate reduction of severe diarrhea in canine acute gastroenteritis after consumption of Visbiome Vet. This placebo-controlled study will compare the safety and efficacy of Visbiome Vet to dietary changes with a specifically formulated medical diet, or antibiotics (metronidazole). "Gastrointestinal disorders are a common cause for pet owners to seek the medical care of a veterinarian," said Al Jergens, DVM, PhD. "Modulating the gut microbiome with high potency probiotics may prove to be a …
Thirteen dogs win Walkin' Pets calendar contest supporting disabled petsSeptember 13, 2018The 2019 Walkin' Pets worldwide calendar contest has announced 13 winners from around the world. This year, the winning dogs hail from eight countries: Thailand, Brazil, Germany, England, United States, Mexico, Italy, and Wales. The champions were selected by popular vote on the Walkin' Pets Facebook page and were announced through a video by the company. The winning dogs range in age from 1 to 11 and are of all sizes and breeds, including a dachshund, a German shepherd, a Siberian husky, French bulldog, and more. Each year, the contest features pets using Walkin' Wheels wheelchairs to help raise awareness of options for disabled pets with mobility challenges. The 2019 calendar is available for pre-order at (888) 253-0777. All proceeds from calendar sales go to the Handicapped Pets Foundation.
California to test pilot program for injured police dogsSeptember 13, 2018California Governor Jerry Brown signed Assembly Bill 1776 on Sept. 6, establishing a pilot program that would authorize medical technicians to provide emergency, ground-based transportation to a veterinary facility for police dogs injured in the line of duty. This bill would authorize the County of San Bernardino to work with the Inland Counties Emergency Medical Agency to conduct a pilot project starting Jan. 1, 2019, in which they collect specified data about the results and submit a report to the Legislature by Jan. 1, 2022. As an exception, there must be no person requiring medical attention or transportation at the scene when the request is made, and the ambulance must have a policy permitting the transportation of an injured police dog. The canine handler must accompany the dog and remain in full control during transport. Additionally, the canine handler remains responsible for any first aid given to the injured police dog during transport.
Boehringer Ingelheim gives support shots for World Rabies Day 2018September 13, 2018Merial, part of Boehringer Ingelheim (BI), announced it will donate 75,000 doses of rabies vaccine to the Global Alliance for Rabies Control (GARC) in recognition of World Rabies Day on Sept. 28. The donation is a result of the Shots for Good initiative, in which BI pledged to donate doses of rabies vaccine for every dose of Purevax, Recombitek, and Imrab vaccine purchased by participating veterinary practices from July 2 to Aug. 10, 2018. The donated vaccines will support a mass dog vaccination campaign in Madagascar to control the disease and limit the potential for reintroduction of rabies from neighboring countries. "The support of our participating veterinary practices made this donation possible," said Zach Mills, DVM, executive director of BI's U.S. Pet Veterinary Professional Services. "BI understands the importance of vaccination to the overall health of pets worldwide. With more than a decade of experience advocating for rabies prevention, the Global Alliance for Rabies Control has the infrastructure to put this donation to good use." GARC will manage the campaign in Madagascar with government veterinary services and international and local nongovernmental organizations. Established protocols will be used to plot and …
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy treatment in 18 dogs. Those that received the vaccine lived more than twice as long as the historical, matched control group, with median survival times of 956 days compared to 423 days. The expanded clinical trial is designed to collect additional safety data for the vaccine in dogs that have undergone amputation of the affected limb and have already completed chemotherapy. If the treatment is found to be as safe and effective as it appeared in the initial clinical trial, Aratana will be given full licensure, allowing it to make the drug commercially available. Live Listeria Vector (AT-014) is created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells. It is designed to supplement standard osteosarcoma treatment of amputation …
Alzheimer's drug used in cognitive dysfunction syndrome clinical trialSeptember 5, 2018Ropesalazine, a drug candidate for Alzheimer's disease (AD), has shown efficacy in a pilot clinical trial conducted for dogs with cognitive dysfunction syndrome (CDS), according to the drug's manufacturer, South Korea-based GNT Pharma. There currently is no cure for CDS, a progressive neurodegenerative disorder of senior dogs characterized by altered interaction with family, disorientation, sleep/wake cycle changes, increased house soiling, and activity change. It is accompanied by nerve cell death, amyloid plaques, and neurofibrillary tangles similar to AD, leading GNT Pharma scientists to design the pilot study to investigate whether Ropesalazine would alleviate signs of CDS, as well. "The companion dogs failed to recognize their owners before the treatment," said Jae Bong Moon, DVM, head of Irion Animal Hospital in Seoul, who led the study. "It was so amazing to see the dogs that wagged their tails for their owners and cuddled up to them within eight weeks of Ropesalazine treatment. [It] appeared to cure CDS." The study was conducted on six companion dogs age 10 or older who revealed severe cognitive dysfunction according to canine cognitive dysfunction and canine dementia rating scales. Within eight weeks following daily oral administration of Ropesalazine, all six dogs returned …
